No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY ITALY

CVC sees an European future for DOC Generici. In the meantime the financing structure is to be finalized

Bebeezby Bebeez
March 21, 2016
Reading Time: 2 mins read
in ITALY, PRIVATE EQUITY
Share on FacebookShare on Twitter

DOC Generici Charterhouse finanziamento Cvc Capital Partners pursuits a European generic pharma platform starting from Italy’s DOC Generici acquisition announced ten days ago for a 650 million euros enterprise value  (see here a previous post by BeBeez), MF Milano Finanza iwrote last Saturday March 19th. DOC Generici is the largest independent generic pharmaceutical company in Italy, with a market share of over 15%

DOC Generici would be part of a European project for consolidating the generic pharamceutical sector. The project however is to be implemented in the medium term and as for now CVC is going to support DOC Generici business as stand alone.

CVC, led in Italy by partner Giampiero Mazza, already owns a stake in Alvogen, together with Singapore’s soverein wealth fund Temasek. The two funds bought their stake from Pamplona private equity fund last June and Alvogen was valued about 2 billion dollars (see here a previous post by BeBeez).

DOC Generici’s strategic plan, which has been agreed with the management (top management will reinvest in the company for about 5-10% of the capital) sees the enlargement of the product range to ophtalmology and nutritional additives on one side and brand empowerment on the other side, as the company wants to grow  the stake of its revenues coming from drugs which are not completely refunded by the national healthcare system.

More in detail, the deal has been conducted through an Italian newco (Debussy spa) which ic controlled by an Italian newco (Debussy Investimenti) which in turn in controlled by Debussy sarl (Luxembourg) owned by CVC funds. In the coming days the structure of the financing package is going to be finalized. For the moment the whole financing has been subscribed by Unicredit which proposed 300 million euros in senior debt and 75 million in second lien both maturing in 7-8 years. Unicredit will proceed then to a syndacation to other banks, with Hsbc among them.

Doc Generici reached about 180 million euros in revenues and 61 millions in ebitda in 2015. Charterhouse who sold the company to CVC, had invested in DOC Generici in 2013 when the group was valued in a range of 320-340 million euros or 7-8x FY 2012 ebitda, which had been 43-44 millions after the group had reached 131.8 millions in revenues that year.

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

Phononic Vibes targets a 20 million turnover ahead of M&A growth, CEO says
FINTECH

Phononic Vibes targets a 20 million turnover ahead of M&A growth, CEO says

July 1, 2025
PRIVATE EQUITY

zvoove Secures Foothold in UK Staffing Market with Acquisition of mywage’s Next-Gen Mid-& Backoffice Platform

July 1, 2025
Italy’s angels & incubators and venture capital weekly roundup. News from BeDimensional, The European Investment Bank, CDP, Eureka! Venture, NovaCapital, Pellan Italia, and more
FINTECH

BeDimensional to launch a 20 million euros round, CEO says

July 1, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post

A US industrial group in talks to buy Euticals and Bitolea from Clessidra fund

A 10% break up fee weights on GS Retail's auction

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart